Dato' Sri Dr Azhari bin Rosman

Cardiologist

Institut Jantung Negara

About

Summary

Dr Azhari Rosman is a Senior Consultant Cardiologist at the National Heart Institute (IJN), serving in multiple leadership roles and actively involved in clinical trials, publications, and scientific meetings.

Full Biography

Dato' Dr Azhari Rosman is a Senior Consultant Cardiologist at the National Heart Institute (IJN). He holds fellowships with the FACC, FESC, and FRCP, reflecting his extensive expertise and recognition in the field of cardiology. In addition to his clinical responsibilities, Dr. Azhari serves as the Chairman of the CPR Faculty and Director of Customer Experience at IJN. He is also a Committee Member of the Academic Board at IJN, contributing to the academic and organizational leadership of the institute. Dr. Azhari is actively involved in shaping the direction of cardiology in Malaysia and the broader region. He serves on the Malaysian Specialty Sub-Committee for Cardiology (SSC), and has held prominent leadership positions, including Past President of the National Heart Association of Malaysia, the Malaysian Society of Hypertension, and the Asia-Pacific Society of Hypertension. Currently, he is the Vice-President of the Malaysian Resuscitation Council and the current Vice-President of the Asia Pacific Society of Cardiology. His professional interests focus on interventional cardiology and cardiovascular risk factors. Dr. Azhari has played a significant role in various landmark and randomized control trials. He has been an Organising Chair and Faculty member at numerous international and regional scientific meetings, demonstrating his commitment to advancing cardiology through education and collaboration. He is also actively involved in publications, teaching, and speaking engagements, further contributing to the dissemination of knowledge in his field. Dr. Azhari has served as an investigator in many international trials and registries. These include the AtoZ Trial, Pravastatin Acute Coronary Treatment (PACT), Ontarget Study, Transend Study (Telmisartan Randomised Assessment Study in ACE-intolerant subjects with cardiovascular disease), Rocket AF, SAFE Study (Septal Pacing for Atrial Fibrillation Suppression Evaluation atherothrombotic events), and PACE Study (Pacing to avoid cardiac Enlargement). He has also contributed to the Cardiac Resynchronization Therapy (CRT) database, and research on genetic mutations and polymorphisms of ABCA1, LCAT, and APO A1 gene among patients with low plasma high-density lipoprotein (HDL) levels. Further, Dr. Azhari has participated in the BIOSOLVE-IV Registry Safety and Performance in De Novo Lesion of Native Coronary Arteries with Magmaris, the Onyx ONE Study (a randomized controlled trial with Resolute Onyx in one month DAPT for high-bleeding risk patients), the DEDICATE REGISTRY (Drug Eluting Stent for Diabetic Patients in Coronary Artery Disease Treatment), and the SELECT STUDY (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity). His involvement in these studies underscores his commitment to advancing clinical practice and improving patient outcomes in cardiology.